JAKARTA – PT Prodia Diagnostic Line, or Proline, inaugurated its latest manufacturing facility in the Jababeka industrial area, Cikarang, on Friday (25/4). The facility is projected to boost production of reagents and diagnostic instruments by three to four times.

Among those attending the inauguration was Dr Günther Gorka, Founder of DiaSys GmbH, who praised the company’s initiative to strengthen self-sufficiency and resilience in the domestic in vitro diagnostic (IVD) supply chain.

Dr Gorka said that supply chain resilience is especially critical amid ongoing geopolitical tensions following US President Donald Trump’s announcement of steep import tariffs earlier this month (2/4).

He urged the global community to push back against Trump’s policies. “Let us remember that the United States only represents about 4% of the world’s population. There is still the remaining 96%. We must oppose this policy,” he asserted during his opening speech.

He added that if the world joins forces to collaborate without depending on US products or following American business practices—particularly in the medical sector—it would significantly benefit the global landscape.

“This is what we are trying to do, and what we are doing together with Proline,” he said.

For reference, DiaSys Diagnostic Systems GmbH is a German manufacturer of diagnostic systems and has been Proline’s official global partner in Indonesia for reagent production since 2010.

Commenting further on Trump’s tariff policy, Dr Gorka expressed hope that medical products would not be burdened with excessively high tariffs.

He noted that Trump had hinted at a regulatory overhaul for pharmaceuticals and diagnostics, but added that the direction of Trump’s policy was “unpredictable.”

“We can predict that something will change, but what, how, how long it will take, and in what form—we have no idea at all,” he concluded. (ZH)